Posted by Michael Wonder on 30 Jun 2026
FDA approves Arcutis’ Zorvye (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children as young as age 2
29 June 2026 - Arcutis Biotherapeutics today announced that the US FDA has approved the supplemental new drug application to expand the indication for Zorvye (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children down to age 2.
Zorvye cream 0.3% is a once-daily, steroid-free topical that is safe, effective, and well tolerated, and is suitable for use anywhere on the body with no limitations on duration of use.
